Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.57 |
| ▸ | CCR2 | P41597 | 2/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.57 |
| ▸ | PRKCG | P05129 | 2/20 | 0.57 |
| ▸ | PRKCB | P05771 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | PRKCA | P17252 | 2/20 | 0.57 |
| ▸ | PRKACA | P17612 | 2/20 | 0.57 |
| ▸ | PRKACG | P22612 | 2/20 | 0.57 |
| ▸ | PRKACB | P22694 | 2/20 | 0.57 |
| ▸ | PRKCH | P24723 | 2/20 | 0.57 |
| ▸ | PRKCI | P41743 | 2/20 | 0.57 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.57 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.57 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567334 | 0.86 | ROCK2 (0.47) | ROCK2ROCK1CCR2PRKD3PRKCG | |
| SCHEMBL4187543 | 0.85 | ROCK2 (0.53) | ROCK2ROCK1CCR2PRKD3PRKCG | |
| SCHEMBL4183290 | 0.85 | ROCK2 (0.53) | ROCK2ROCK1CCR2PRKD3PRKCG | |
| SCHEMBL4194658 | 0.85 | ROCK2 (0.59) | ROCK2ROCK1CCR2PRKD3PRKCG | |
| SCHEMBL567678 | 0.85 | CKS1B (0.47) | ROCK2ROCK1CCR2PRKD3PRKCG | |
| SCHEMBL18428243 | 0.85 | CHRM1 (0.55) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL17228271 | 0.85 | CHRM1 (0.61) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL18428229 | 0.85 | CHRM1 (0.61) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL22971612 | 0.84 | ROCK2 (0.59) | ROCK2ROCK1CCR2PRKD3PRKCG | |
| SCHEMBL4183287 | 0.84 | ROCK2 (0.62) | ROCK2ROCK1CCR2PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | disclosed |
| WO-2022262548-A1 | PREPARATION METHOD FOR COMPOUND FASUDIL HYDROCHLORIDE | 华东理工大学 | 2022-12-22 | — | — | WO | disclosed |
| US-7867999-B1 | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100048540-A1 | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048540-A1 | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, HYOU1 | ROCK2 380/4885ROCK1 289/4885CCR2 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.